CD276 and cancer: Subsequent analysis also demonstrated a clear relationship between GPX4 expression and key immune checkpoints such as VEGFB, TGFB1, CD276, TNFRSF18, and TNFRSF4 across most cancer types (Supplementary Figure S7).